Managing Progression in Relapsing-Remitting Multiple Sclerosis

Clyde E. Markowitz, MD


June 04, 2020

Multiple oral and intravenous disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), and all have demonstrated efficacy in reducing both clinical relapses and development of new MRI-detected lesions. Despite this efficacy, individual patients may experience some breakthrough disease and need to consider changing therapies.

Dr Clyde Markowitz, director of the Penn Comprehensive Multiple Sclerosis Center in Philadelphia, Pennsylvania, discusses considerations for determining breakthrough disease in patients with both new and established RRMS. He also reports on the current approach to changing disease-modifying therapies and the importance of the shared–decision-making model.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.